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Introduction: To determine whether the postchemoradiotherapy 
(post-CRT) pathologic stage predicts the outcomes of patients with 
locally advanced esophageal squamous cell carcinoma (ESCC) 
undergoing preoperative CRT followed by surgery.
Methods: From three phase II trials of preoperative CRT for locally 
advanced ESCC, 140 patients were included. Preoperative CRT 
comprised twice weekly paclitaxel and cisplatin-based regimens and 
40-Gy radiotherapy in 20 fractions. The post-CRT pathologic stage 
was classified according to the American Joint Committee on Cancer, 
7th edition staging system. The prognostic effects of clinicopatho-
logic factors were analyzed using Cox regression.
Results: With a median follow-up of 61.9 months, the median pro-
gression-free survival (PFS) and overall survival (OS) of the entire 
cohort were 24.5 and 30.9 months, respectively. The post-CRT patho-
logic stage was 0 in 34.5%, I in 12.9%, II in 29.3%, III in 13.6%, and 
ypT0N1-2 in 6.4% of the patients. The median PFS was 47.2, 25.9, 
16.0, 9.4, and 15.1 months, and the median OS was 57.4, 34.1, 26.2, 
14.1, and 17.6 months for patients with post-CRT pathologic stage 0, 
I, II, III, and ypT0N1-2, respectively. In multivariate analysis, perfor-
mance status (p < 0.001), tumor location (p = 0.016), and extranodal 
extension (p = 0.024) were independent prognostic factors for PFS, 
whereas performance status (p < 0.001) and post-CRT pathologic 
stage (p = 0.027) were independent prognostic factors for OS.
Conclusions: The post-CRT pathologic stage classified by American 
Joint Committee on Cancer, 7th edition staging system predicted the 
survival of locally advanced ESCC patients who underwent preoper-
ative paclitaxel and cisplatin-based CRT followed by esophagectomy.
Key Words: Esophageal neoplasms, Squamous cell carcinoma, 
Prognosis, Combined modality therapy.
(J Thorac Oncol. 2015;10: 1481–1489)
Esophageal cancer is a highly lethal disease that caused more than 400,000 deaths worldwide in 2008. The two major 
histology subtypes of esophageal cancer, adenocarcinoma and 
squamous cell carcinoma, exhibit distinct geographic distribu-
tions. Esophageal adenocarcinoma (EAC) is the dominant his-
tology of esophageal cancer diagnosed in Western countries, 
whereas esophageal squamous cell carcinoma (ESCC) is the 
prominent subtype in Eastern countries.1 EAC and ESCC have 
different risk factors and genetic alterations and are distinct 
disease entities.2,3
Patients with locoregional esophageal cancer have 
typically been treated with surgery or definitive chemora-
diotherapy (CRT); however, only 15% to 25% of them expe-
rience long-term, disease-free survival.4–6 Multimodality 
therapy, particularly preoperative CRT followed by surgery, 
has become the research focus for locoregional esophageal 
cancer since the 1990s. A recent meta-analysis based on 17 
randomized trials evaluating the survival effect of preop-
erative treatment for resectable esophageal cancer revealed 
that the pooled hazard ratio of preoperative CRT was 0.78 
(95% confidence interval [CI]: 0.70–0.88), corresponding to 
an absolute survival benefit at 2 years of 8.7%. The survival 
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benefits for preoperative CRT were similar in EAC and ESCC 
subtypes.7 The Chemoradiotherapy for Oesophageal Cancer 
Followed by Surgery Study (CROSS), a large-scale random-
ized phase III study comparing preoperative paclitaxel and 
carboplatin-CRT with surgery alone, unequivocally proved a 
survival benefit of preoperative CRT in locoregional esoph-
ageal cancer. The subgroup analysis of the CROSS study 
revealed that ESCC patients appeared to derive more overall 
survival (OS) benefit than did EAC patients.8
Several prognostic factors, such as pathologic com-
plete response (pCR) and R0 resection, have been identified 
for patients who received preoperative CRT followed by sur-
gery.9 However, the prognostic significance of the post-CRT 
pathologic stage assessed by the often used American Joint 
Committee on Cancer (AJCC) tumor, node, metastasis (TNM) 
staging system has been controversial. Two previous United 
States-based studies enrolled EAC patients predominantly and 
evaluated the prognostic significance of the post-CRT patho-
logic stage determined by the 6th edition of the AJCC (AJCC-
6). The two studies reported conflicting results.10,11 No similar 
studies have since been reported in ESCC patients.
To evaluate the prognostic effect of the post-CRT patho-
logic stage for ESCC patients, we assessed the post-CRT 
pathologic stages classified by the AJCC 7th edition staging 
system (AJCC-7), which was released in 2009 and incor-
porates a more sophisticated N staging, in a large cohort of 
ESCC patients who had been treated with preoperative pacli-
taxel and cisplatin-based CRT followed by surgery for their 
locally advanced diseases.
PATIENTS AND METHODS
Study Cohort
The study population comprised patients with locally 
advanced ESCC, retrospectively identified from three pro-
spective phase II studies evaluating the efficacy of preop-
erative CRT based on a twice weekly paclitaxel/cisplatin 
regimen, followed by surgery for locally advanced esopha-
geal cancer at National Taiwan University Hospital (NTUH), 
Taipei, Taiwan between 2000 and 2012. Patients enrolled 
into the three clinical trials were required to have treatment-
naive, pathologically proven, and locally advanced esophageal 
cancer (stage T3N0 or T1-3N1 in AJCC-6, or selected M1a 
diseases with primary tumors, involving lymph nodes (LNs) 
that could be curatively treated using radiation and surgery). 
Patients underwent esophagogastroduodenoscopy, endoscopic 
ultrasonography, a computed tomography scan, fluorodeoxy-
glucose positron emission tomography which was optional for 
one study and was mandatory in the other two, and bronchos-
copy for staging workup. The other inclusion and exclusion 
criteria of the three phase II studies were similar, including 
adequate hematological, hepatic, and renal function reserves, 
no distant metastases, no prior or concomitantly diagnosed 
malignant diseases including head and neck squamous cell 
carcinoma, good performance status (Eastern Cooperative 
Oncology Group- Performance Status [ECOG-PS] 0–2), and 
written informed consent. This study was approved by the 
Institutional Research Ethics Committee of NTUH.
Treatment and Follow-Up
The preoperative CRT regimens of the three phase II 
studies included (1) paclitaxel-cisplatin (TP)-CRT com-
posed of twice weekly paclitaxel and cisplatin, admin-
istered as paclitaxel 35 mg/m2 on Monday and Thursday 
and cisplatin 15 mg/m2 on Tuesday and Friday, plus 
radiation with 40 Gy, administered in 20 fractions, (2) 
TP-CRT plus cetuximab, administered as 400 mg/m2 3 to 
5 days before the start of CRT followed by 250 mg/m2/wk 
for 4 weeks, and (3) one cycle of systemic chemotherapy with 
TP plus weekly 24h-infusion of high-dose 5-fluorouracil and 
leucovorin (TP-HDFL) (administered as paclitaxel 80 mg/m2 
on day 1 and day 8, cisplatin 35 mg/m2 on day 2 and day 9, 
5-fluorouracil 2000 mg/m2 plus leucovorin 300 mg/m2 24-hour 
intravenous infusion on day 2 and day 9) followed by TP-CRT 
starting from day 22 of one-cycle chemotherapy. An esopha-
gectomy plus a 2-field LN dissection was performed 4 to 6 
weeks after completing CRT. No further adjuvant therapy was 
routinely provided. Patients were subsequently followed with 
regular visits every 2 to 3 months and a periodical survey by 
esophagogastroduodenoscopy and computed tomography 
every 4 to 6 months for at least 5 years. The three studies were 
approved by the Institutional Research Ethics Committee of 
NTUH and had been previously publicized on ClinicalTrial.
gov. The details and results of the studies have been previously 
published or otherwise presented.12–14 There are no significant 
differences in pCR rate, progression-free survival (PFS), and 
OS among patients of the three treatment groups.
Post-CRT Pathologic Stage
The post-CRT pathologic stage was classified according 
to the AJCC-7. The pCR was defined as no residual invasive 
tumor cell in the primary site and dissected LNs. We classified 
patients into five groups, including pathologic stage 0, stage 
I, stage II, stage III, and ypT0N1-2 for subsequent prognostic 
analyses.
Statistical Analysis
The follow-up data were compiled as of December 31, 
2013. The primary objective of this study was to determine 
whether the post-CRT pathologic stage classified by AJCC-7 
could predict the prognosis of patients with locally advanced 
ESCC treated by preoperative paclitaxel and cisplatin-based 
CRT followed by surgery. OS was defined from the first day of 
enrolling in clinical studies to the day of death from any cause, 
or the last follow-up (censored). PFS was defined from the first 
day of enrolling in clinical studies to the day of recurrence, 
death from any cause, or the last follow-up without recurrence 
(censored). Descriptive statistics was used for the baseline 
clinical characteristics and the post-CRT pathologic findings. 
Chi-square test was used to examine the difference of clinical 
factors between study cohort and all ESCC patients group. The 
Kaplan–Meier method was used to estimate patients’ survivals. 
The association of clinicopathologic variables with PFS or OS 
was examined univariately by Cox regression. The statistically 
significant factors found in univariate analysis, defined by p 
value less than 0.05, were further evaluated for their association 
with PFS or OS multivariately by Cox regression. We did not 
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include pCR in the Cox regression model in multivariate analy-
sis because of the inevitably high correlation with the post-CRT 
pathologic stage according to AJCC-7. All data analyses were 
performed with SPSS 20.0 (Chicago, IL).
RESULTS
Patient Characteristics
A total of 215 patients with locally advanced esophageal 
cancer were enrolled into the three phase II studies at our center. 
Excluding patients with initial M1b stage (n = 9), those who 
withdrew from the clinical trials (n = 6), and those who exhib-
ited adenocarcinoma in histology (n = 6), we identified 194 
patients with ESCC. Among them, 54 patients did not receive 
planned surgery after completing the initial preoperative CRT 
and were thus excluded from the analysis. Finally, 140 ESCC 
patients constituted the study cohort of this report (Fig. 1).
The major clinicopathologic characteristics of the study 
cohort patients are listed in Table 1. Their median age was 
53.4 years (range, 34.3–74.3 yr). The majority were men 
(94.3%) with good ECOG-PS (0 or 1; 95%). At diagnosis, the 
clinical stage according to AJCC-6 was stage IIA-B, stage III, 
and stage IVA in 9 (6%), 121 (87%), and 10 patients (7%), 
respectively; the primary tumor was located at the cervical and 
upper esophagus, middle esophagus, and lower esophagus in 
39 (28%), 68 (49%), and 33 (23%) patients, respectively. The 
median duration from completing radiation to surgery was 44 
days (range, 18–98 d). No significant differences existed in 
clinical features between the study cohort (n = 140) and all 
ESCC patients enrolled in the three phase II trials (n = 194).
Post-CRT Pathologic Stage Classified by AJCC-7
The pathologic T0 or Tis, T1, T2, and T3 were found in 
41.4%, 12.9%, 20.7%, and 22.1% of the study cohort, respec-
tively. Four patients had a residual primary tumor, but the 
pathologic T stage could not be classified. The median number 
of LN dissections was 19 (range, 2–96). One patient who 
underwent curative esophagectomy without LN dissection 
was designated as not analyzable because of the importance 
of pathologic N stages. The pathologic N0, N1, N2, and N3 
were identified in 70.7%, 19.3%, 8.6%, and 0.7% of the study 
cohort, respectively. Nine percent of patients had a positive or 
close (≤1 mm) margin. Extranodal extension (ENE) was iden-
tified in 10.7% of the patients. Lymphovascular or perineural 
invasion was observed in 11.4% of the patients. The pCR to 
preoperative CRT (i.e., post-CRT pathologic stage ypT0 or 
TisN0) was observed in 48 patients (34.3%). The post-CRT 
pathologic findings are summarized in Table 2.
Survival Analysis
After the median follow-up of 61.9 months (range, 
24.7–167.8 mo), the median PFS of all patients was 24.5 
months. For patients with pathologic T0 or Tis, T1, T2, and 
T3, the median PFS was 39.6, 29.3, 12.2, and 11.3 months, 
respectively (p = 0.051). The median PFS for patients with 
pathologic N0, N1, N2, and N3 was 28.3, 15.1, 8.6, and 
6.9 months, respectively (p < 0.001). The median PFS for 
patients with pathologic stage 0, stage I, stage II, stage III, 
and ypT0N1-2 was 47.2, 25.9, 16.0, 9.4, and 15.1 months, 
respectively (p = 0.001).
The median OS of all patients was 30.9 months. The 
median OS for patients with pathologic T0 or Tis, T1, T2, 
and T3 was 41.2, 36.6, 23.9, and 18.9 months, respectively 
FIGURE 1.  Study cohort. TP-CRT, chemoradiotherapy with 
twice weekly paclitaxel and cisplatin; EAC, esophageal adeno-
carcinoma; ESCC, esophageal squamous cell carcinoma.
TABLE 1.  Patient Characteristics
Characteristics
All Patients 
(N = 194)
Study Cohort 
(N = 140) P Value
Age, yr (<60/≥60) 130/64 107/33 0.061
  Median 55.5 53.4
  Range 34.3–79.6 34.3–74.3
Sex (male/female) 182/12 132/8 0.858
ECOG-PS (0–1/2) 181/13 133/7 0.518
Clinical T (2/3/4) 4/185/5 4/134/2 0.695
Clinical N (0/1) 15/179 8/132 0.472
Clinical M1a (+/-) 182/12 130/10 0.728
Clinic stage (IIA and IIB/III/IVA) 15/167/12 9/121/10 0.858
Location (C and U/M/L) 60/90/44 39/68/33 0.832
Albumin, g/dL (<4/≥4/missing) 34/156/4 23/113/4 0.818
WBC (<10,000/≥10,000/missing) 156/34/4 110/26/4 0.079
Days from radiation completed to surgery
  Median 44
  Range 18–98
Preoperative therapy protocol
  TP-CRT 90 57 0.587
  Cetuximab/TP-CRT 46 37
  TP-HDFL then TP-CRT 58 46
C, cervical; U, upper thoracic; M, middle thoracic; L, lower thoracic; WBC, white 
blood cell count (/μL); TP-CRT, chemoradiotherapy with twice weekly paclitaxel and 
cisplatin; Cetuximab/TP-CRT, cetuximab plus TP-CRT; TP-HDFL then TP-CRT, one-
cycle induction chemotherapy with paclitaxel and cisplatin plus 24-hour infusion of 
high-dose 5-fluorouracil and leucovorin followed by TP-CRT; ECOG-PS, Eastern 
Cooperative Oncology Group-performance status.
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(p = 0.115). For patients with pathologic N0, N1, N2, and N3, 
the median OS was 39.5, 23.9, 9.6, and 8.8 months, respec-
tively (p < 0.001). The median OS for patients with pathologic 
stage 0, stage I, stage II, stage III, and ypT0N1-2 was 57.4, 
34.1, 26.2, 14.1, and 17.6 months, respectively (p = 0.002). 
The PFS and OS curves for patients with distinct pathologic 
T, N, and M stages, estimated by the Kaplan–Meier method, 
are shown in Figure 2.
Prognostic Significance of Post-CRT 
Pathologic Staging and Other Factors
In univariate analysis, sex (p = 0.038), ECOG-PS 
(p = 0.001), primary tumor location (p = 0.006), pathologic 
N (p < 0.001), pathologic stage according to the AJCC-7 
(p = 0.002), ENE (p < 0.001), and pCR (p = 0.004) were iden-
tified as significant factors associated with PFS. ECOG-PS 
(p = 0.001), primary tumor location (p = 0.017), pathologic 
N (p < 0.001), pathologic stage according to the AJCC-7 
(p = 0.004), ENE (p = 0.007), and pCR (p = 0.008) were iden-
tified as significant factors associated with OS. The univari-
ate analysis performed using Cox regression is summarized 
in Table 3.
Multivariate analysis, including all significant factors 
identified in the univariate analyses, indicated that ECOG-PS 
(p < 0.001), primary tumor location (p = 0.016), and ENE 
(p = 0.024) were independent prognostic factors for PFS. We 
observed a trend for pathologic stage according to the AJCC-
7, for predicting PFS, although it did not reach statistical sig-
nificance (p = 0.085).
In multivariate analysis of OS, we found that ECOG-PS 
(p < 0.001) and pathologic stage according to the AJCC-7 
(p = 0.027) were independent prognostic factors. The mul-
tivariate analyses using Cox regression are summarized in 
Table 4.
DISCUSSION
Increasing data have emerged supporting the superior-
ity of preoperative CRT followed by surgery, compared with 
surgery alone in treating locoregional esophageal cancer.7,8 
Although pCR has long been recognized as a crucial factor 
in conferring favorable outcomes in patients receiving pre-
operative CRT, the prognostic effect of the post-CRT patho-
logic stage classified by the often used AJCC TNM staging 
system remains uncertain. Two previous reports studying 
the significance of the post-CRT pathologic stage classified 
by the AJCC-6 in EAC patients did not achieve consistent 
results.10,11 In this study, we retrospectively analyzed a large 
cohort of locally advanced ESCC patients who had been 
treated with preoperative paclitaxel/cisplatin-based CRT and 
found that the post-CRT pathologic stage classified by the 
AJCC-7 was an independent prognostic factor for patient 
OS. This is the first report addressing the prognostic signifi-
cance of the post-CRT pathologic stage, using the AJCC sys-
tem, for ESCC.
Our conclusion is consistent with previous reports 
that the amount of pathologic LN involvement or the patho-
logic node-positive status is a significant prognostic fac-
tor in ESCC patients treated with preoperative CRT.15–17 In 
our patient cohort, the post-CRT pathologic N status was 
the most significant factor affecting prognosis in the uni-
variate analysis. In the AJCC-7, the presence or absence of 
LN involvement largely differentiates the tumor staging as 
stage III or stage I/II, with the exception of T1-2N1, which 
is classified as stage IIB. However, our data also showed that 
patients in post-CRT stage I had better survival outcomes 
than did patients in post-CRT stage II, indicating that fac-
tors other than pathologic N status, such as T stages, also 
have a prognostic effect on ESCC patients receiving preop-
erative CRT.
Our analysis also indicated that PS is an independent 
prognostic factor for PFS and OS, and primary tumor location 
and ENE are additional independent prognostic factors for PFS. 
TABLE 2.  Postchemoradiotherapy Pathologic Findings
Characteristics (N =140) %
T
  0 or Tis 58 41.4
  1 18 12.9
  2 29 20.7
  3 31 22.1
  4 0 0
  N/A 4 2.9
N
  0 99 70.7
  1 27 19.3
  2 12 8.6
  3 1 0.7
  N/A 1 0.7
Median number of total lymph nodes (range) 19 (2–96)
AJCC 7th stage
  0 48 34.3
  IA/IB 12/6 12.9
  IIA/IIB 19/22 29.3
  IIIA/IIIB/IIIC 14/4/1 13.6
  ypT0N1/ypT0N2 5/4 6.4
  N/A 5 3.6
Margin
  Free 127 90.7
  Close (≤1 mm) or involved 13 9.3
Extranodal extension
  Negative 124 88.6
  Positive 15 10.7
  N/A 1 0.7
Lymphovascular or perineural invasion
  Negative 124 88.6
  Positive 16 11.4
Pathologic complete remission (pCR)a
  pCR 48 34.3
  Non-pCR 91 65.0
  N/A 1 0.7
apCR: no residual invasive tumor cell in primary site and dissected lymph nodes.
AJCC, American Joint Committee on Cancer; N/A, not available.
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Kim et al.18 previously reported that PS was a prognostic factor 
for locally advanced resectable ESCC patients who underwent 
preoperative CRT with a platinum/fluoropyrimidine-based regi-
men followed by surgery. Two other studies of ESCC patients 
who underwent surgery alone also revealed that ENE was an 
independent prognostic factor with negative survival effect.19,20
All patients enrolled in this analysis were treated with 
preoperative CRT with a paclitaxel/cisplatin-based regimen 
FIGURE 2.  Kaplan–Meier estimates of progression-free survival (A, C, and E) and overall survival (B, D, and F) of postchemora-
diotherapy pathologic stages according to the American Joint Committee on Cancer, 7th edition.
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TABLE 3.  Univariate Analysis of Progression-Free Survival and Overall Survival (Cox Regression)
Variable
Progression-Free Survival Overall Survival
HR (95% CI) P Value HR (95% CI) P Value
Age (yr)
  <60 (reference) 1.00 1.00
  ≥60 1.16 (0.73,1.85) 0.522 1.22 (0.76,1.96) 0.416
Sex
  Female (reference) 1.00 1.00
  Male 3.38 (1.07,10.72) 0.038 3.04 (0.96,9.65) 0.059
ECOG-PS
  0–1 (reference) 1.00 1.00
  2 3.73 (1.70,8.16) 0.001 3.98 (1.81,8.74) 0.001
Clinical T 0.408 0.445
  T2 (reference) 1.00 1.00
  T3 1.98 (0.49,8.04) 0.341 1.74 (0.43,7.06) 0.441
  T4 3.84 (0.54,27.45) 0.180 3.55 (0.50,25.30) 0.207
Clinical N
  N0 (reference) 1.00 1.00
  N1 1.21 (0.45,3.31) 0.705 1.08 (0.39,2.94) 0.886
Clinical M1a
  (−) (reference) 1.00 1.00
  (+) 1.54 (0.74,3.18) 0.248 1.06 (0.46,2.44) 0.884
AJCC 6th stage 0.432 0.914
  IIA/IIB (reference) 1.00 1.00
  III 1.32 (0.53,3.26) 0.548 1.20 (0.49,2.98) 0.689
  IVA 1.99 (0.65,6.10) 0.229 1.26 (0.39,4.15) 0.699
Location 0.006 0.017
  C and U (reference) 1.00 1.00
  M 0.48 (0.3,0.76) 0.002 0.50 (0.31,0.81) 0.004
  L 0.76 (0.45,1.29) 0.312 0.72 (0.42,1.26) 0.251
Albumin (g/dL)
  <4 (reference) 1.00 1.00
  ≥4 1.07 (0.62,1.85) 0.798 0.99 (0.57,1.71) 0.968
WBC
  <10,000 (reference) 1.00 1.00
  ≥10,000 0.87 (0.52,1.46) 0.601 0.84 (0.49,1.44) 0.522
Preoperative therapy protocol 0.890 0.362
  Cetuximab/TP-CRT(reference) 1.00 1.00
  TP-CRT 1.13 (0.68,1.88) 0.631 1.47 (0.86,2.52) 0.159
  TP-HDFL then TP-CRT 1.07 (0.62,1.85) 0.804 1.36 (0.76,2.44) 0.302
Pathologic T 0.057 0.123
  0 or Tis (reference) 1.00 1.00
  T1 1.20 (0.63,2.27) 0.578 1.07 (0.54,2.11) 0.851
  T2 1.56 (0.90,2.70) 0.110 1.43 (0.82,2.50) 0.207
  T3 2.00 (1.20,3.33) 0.008 1.84 (1.09,3.11) 0.023
Pathologic N <0.001 <0.001
  N0 (reference) 1.00 1.00
  N1 1.48 (0.90,2.46) 0.126 1.29 (0.76,2.19) 0.350
  N2 3.71 (1.97,6.99) <0.001 4.07 (2.15,7.70) <0.001
  N3 7.19 (0.96,53.77) 0.055 9.98 (1.31,75.85) 0.026
(Continued)
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Pathologic AJCC 7th stage 0.002 0.004
  0 (reference) 1.00 1.00
  IA/IB 1.46 (0.75,2.85) 0.264 1.34 (0.65,2.73) 0.428
  IIA/IIB 1.68 (1.00,2.85) 0.055 1.63 (0.95,2.81) 0.079
  IIIA/IIIB/IIIC 3.57 (1.91,6.68) <0.001 3.19 (1.67,6.07) <0.001
  ypT0N1/ypT0N2 2.55 (1.15,5.65) 0.021 2.9 (1.33,6.62) 0.008
Margin
  Free (reference) 1.00 1.00
  Close (≤1 mm) or involved 1.37 (0.71,2.63) 0.354 1.41 (0.73,2.72) 0.310
Extranodal extension
  Negative (reference) 1.00 1.00
  Positive 3.24 (1.80,5.82) <0.001 2.33 (1.26,4.33) 0.007
Lymphovascular or perineural invasion
  Negative (reference) 1.00 1.00
  Positive 1.75 (0.97,3.16) 0.062 1.80 (0.98,3.33) 0.060
Pathologic complete remission (pCR)
  pCR (reference) 1.00 1.00
  non-pCR 1.93 (1.23,3.04) 0.004 1.88 (1.18,3.00) 0.008
C, cervical; U, upper thoracic; M, middle thoracic; L, lower thoracic; WBC, white blood cell count (/μL); TP-CRT, concurrent chemoradiotherapy with twice weekly paclitaxel and 
cisplatin; Cetuximab/TP-CRT, cetuximab plus TP-CRT; TP-HDFL then TP-CRT, one-cycle induction chemotherapy with paclitaxel and cisplatin plus 24-hour infusion of high-dose 
5-fluorouracil and leucovorin followed by TP-CRT; AJCC, American Joint Committee on Cancer; ECOG-PS, Eastern Cooperative Oncology Group-Performance Status; HR, hazard 
ratio; CI, confidence interval. 
P values less than 0.05, defined as statistically significant, are shown in bold.
TABLE 4.  Multivariate Analysis of Progression-Free Survival and Overall Survival (Cox Regression)
Variable
Progression-Free Survival Overall Survival
HR (95% CI) P Value HR (95% CI) P Value
Sex
  Female (reference) 1.00 1.00
  Male 2.81 (0.87,9.09) 0.083 2.33 (0.72,7.54) 0.160
ECOG-PS
  0–1 (reference) 1.00 1.00
  2 5.64 (2.25,14.10) <0.001 6.03 (2.37,15.34) <0.001
Location 0.016 0.077
  C and U (reference) 1.00 1.00
  M 0.48 (0.29,0.80) 0.004 0.56 (0.34,0.93) 0.024
  L 0.71 (0.40,1.25) 0.231 0.75 (0.42,1.35) 0.340
Pathologic AJCC 7th stage 0.085 0.027
  0 (reference) 1.00 1.00
  IA/IB 1.53 (0.77,3.06) 0.224 1.50 (0.72,3.15) 0.281
  IIA/IIB 1.80 (1.03,3.12) 0.038 1.81 (1.01,3.23) 0.045
  IIIA/IIIB/IIIC 2.59 (1.26,5.32) 0.010 2.96 (1.45,6.04) 0.003
  ypT0N1/ypT0N2 2.07 (0.90,4.79) 0.087 2.77 (1.18,6.51) 0.019
Extranodal extension
  Negative (reference) 1.00 1.00
  Positive 2.35 (1.12,4.94) 0.024 1.40 (0.67,2.94) 0.375
C, cervical; U, upper thoracic; M, middle thoracic; L, lower thoracic; AJCC, American Joint Committee on Cancer; ECOG-PS, Eastern Cooperative Oncology Group-Performance 
Status; HR, hazard ratio; CI, confidence interval.
TABLE 3.  (Continued)
Variable
Progression-Free Survival Overall Survival
HR (95% CI) P Value HR (95% CI) P Value
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plus a radiation dose with 40 Gy before surgery. This regi-
men is similar to that reported in the CROSS study, whereby 
patients received weekly paclitaxel/carboplatin plus a radi-
ation dose of 41.4 Gy administered in 23 fractions before 
surgery. The median survival time of our patient cohort was 
inferior to that reported in the CROSS study (median, 30.9 
versus 49.4 mo). This survival difference might have been 
because of patients in more advanced-stages being enrolled 
in our study compared with the CROSS study (clinical T3, 
96% versus 84%; clinical N1, 94% versus 65%), different 
inclusion and exclusion criteria (e.g., patients whose tumors 
were longer than 8 cm or wider than 5 cm, and patients who 
lost more than 10% of their body weight were excluded from 
the CROSS study), and different patient populations regard-
ing their primary tumor location (a higher percentage of 
cervical, upper, and middle thoracic primary tumors in our 
study than in the CROSS study). The pCR rate in our study 
(34.3%) was comparable with those reported in previous 
phase III studies.8,21,22
The prognosis of ypT0N1-2 patients was similar to 
pathologic stage III patients in this current study. A previous 
study revealed that the prognosis of ypT0N1 EAC patients was 
similar to pathologic stage II patients.23 Another retrospective 
study evaluating the outcome of ESCC patients treated with 
preoperative CRT revealed that those with residual viable 
cancer cells only in the LN have similar survival outcomes 
as patients with pCR.24 Our result is inconsistent with these 
studies. Further studies are warranted to define the prognosis 
of ypT0N-positive patients who are treated with preoperative 
CRT for locoregional esophageal cancer.
This study has several limitations. First, we did not 
record the differentiation of cancer cells, which has been 
included as a parameter to be combined with TNM status 
and location of the primary tumor for a complete staging of 
esophageal cancer according to the AJCC-7. Nevertheless, 
the cancer differentiation status can only affect the allo-
cation of certain stage I or stage II cases (i.e., T2-3N0G1 
of lower thoracic ESCC is classified as stage IB, whereas 
T2-3N0G2-3 is classified as stage IIA). Second, patients 
were selected from three sequential clinical trials in a single 
institute between 2000 and 2012. The clinical trial patient 
population might differ slightly from the typical patient pop-
ulation in actual practice, and supportive and medical care 
might have improved or changed significantly over this rela-
tively long patient-enrollment period. However, the clinical 
trial patient population ensured that relevant clinicopatho-
logical factors were collected prospectively. Our study repre-
sents a large ESCC patient population that was treated with 
paclitaxel/platinum-CRT, the contemporary regimen confer-
ring survival benefit.
In summary, our retrospective analysis indicates that 
post-CRT pathological staging according to the AJCC-7 
is a significant prognostic factor for patients with locally 
advanced ESCC who underwent preoperative paclitaxel/cis-
platin-based CRT followed by esophagectomy. This finding 
may help stratify locally advanced ESCC patients for further 
studies investigating novel postoperative approaches. Further 
studies are warranted to confirm the prognostic significance 
of post-CRT pathological staging and its usefulness in the 
treatment of ESCC.
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